A citation-based method for searching scientific literature

Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. N Engl J Med 2008
Times Cited: 4416







List of co-cited articles
508 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
29

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
872
23

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
16

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
15

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
419
15

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
14

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
13

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
12

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
J Shepherd, S M Cobbe, I Ford, C G Isles, A R Lorimer, P W MacFarlane, J H McKillop, C J Packard. N Engl J Med 1995
12

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga,[...]. N Engl J Med 2019
550
12


Low-dose colchicine for secondary prevention of cardiovascular disease.
Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson. J Am Coll Cardiol 2013
479
11

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C LaRosa, Scott M Grundy, David D Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M Gotto, Heiner Greten, John J P Kastelein, James Shepherd,[...]. N Engl J Med 2005
11

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Salim Yusuf, Jackie Bosch, Gilles Dagenais, Jun Zhu, Denis Xavier, Lisheng Liu, Prem Pais, Patricio López-Jaramillo, Lawrence A Leiter, Antonio Dans,[...]. N Engl J Med 2016
457
11

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
11

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
11


The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F M Sacks, M A Pfeffer, L A Moye, J L Rouleau, J D Rutherford, T G Cole, L Brown, J W Warnica, J M Arnold, C C Wun,[...]. N Engl J Med 1996
10

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
968
10




Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
9


Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P M Ridker, M Cushman, M J Stampfer, R P Tracy, C H Hennekens. N Engl J Med 1997
8

C-reactive protein levels and outcomes after statin therapy.
Paul M Ridker, Christopher P Cannon, David Morrow, Nader Rifai, Lynda M Rose, Carolyn H McCabe, Marc A Pfeffer, Eugene Braunwald. N Engl J Med 2005
8

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Stephen Kaptoge, Emanuele Di Angelantonio, Gordon Lowe, Mark B Pepys, Simon G Thompson, Rory Collins, John Danesh. Lancet 2010
8

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
7



High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan, Larry B Goldstein, Michael Hennerici, Amy E Rudolph, Henrik Sillesen, Lisa Simunovic, Michael Szarek, K M A Welch,[...]. N Engl J Med 2006
7

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton J M de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema,[...]. Lancet 2010
7

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
Thomas A Pearson, George A Mensah, R Wayne Alexander, Jeffrey L Anderson, Richard O Cannon, Michael Criqui, Yazid Y Fadl, Stephen P Fortmann, Yuling Hong, Gary L Myers,[...]. Circulation 2003
6


Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
Eric Bruckert, Gilles Hayem, Sylvie Dejager, Caroline Yau, Bernard Bégaud. Cardiovasc Drugs Ther 2005
813
6

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
G G Schwartz, A G Olsson, M D Ezekowitz, P Ganz, M F Oliver, D Waters, A Zeiher, B R Chaitman, S Leslie, T Stern. JAMA 2001
6

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
James A de Lemos, Michael A Blazing, Stephen D Wiviott, Eldrin F Lewis, Keith A A Fox, Harvey D White, Jean-Lucien Rouleau, Terje R Pedersen, Laura H Gardner, Robin Mukherjee,[...]. JAMA 2004
989
6

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Donna K Arnett, Roger S Blumenthal, Michelle A Albert, Andrew B Buroker, Zachary D Goldberger, Ellen J Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J William McEvoy,[...]. Circulation 2019
6

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard,[...]. Eur Heart J 2015
724
6

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Connie B Newman, David Preiss, Jonathan A Tobert, Terry A Jacobson, Robert L Page, Larry B Goldstein, Clifford Chin, Lisa R Tannock, Michael Miller, Geetha Raghuveer,[...]. Arterioscler Thromb Vasc Biol 2019
217
6

Effect of statins on skeletal muscle function.
Beth A Parker, Jeffrey A Capizzi, Adam S Grimaldi, Priscilla M Clarkson, Stephanie M Cole, Justin Keadle, Stuart Chipkin, Linda S Pescatello, Kathleen Simpson, C Michael White,[...]. Circulation 2013
294
6

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Paul M Ridker, Matt Devalaraja, Florian M M Baeres, Mads D M Engelmann, G Kees Hovingh, Milana Ivkovic, Larry Lo, Douglas Kling, Pablo Pergola, Dominic Raj,[...]. Lancet 2021
65
9

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno,[...]. Eur Heart J 2021
282
6

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
Salim Yusuf, Steven Hawken, Stephanie Ounpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos,[...]. Lancet 2004
5

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christina Chung, Anne Peasey, Roman Pfister,[...]. Lancet 2012
644
5

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. J Am Coll Cardiol 2019
911
5

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
5


Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Steven E Nissen, E Murat Tuzcu, Paul Schoenhagen, B Greg Brown, Peter Ganz, Robert A Vogel, Tim Crowe, Gail Howard, Christopher J Cooper, Bruce Brodie,[...]. JAMA 2004
5

Pleiotropic Effects of Statins on the Cardiovascular System.
Adam Oesterle, Ulrich Laufs, James K Liao. Circ Res 2017
493
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.